A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Trial Profile

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Insulin 287 (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 05 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Apr 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 May 2015 to 1 Jun 2015.
    • 28 Apr 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 May 2015 to 1 Jun 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top